Trials / Terminated
TerminatedNCT02992977
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Agenus Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
Detailed description
This is an open-label Phase 1 study to determine the safety and tolerability of single-agent treatment with AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer that is refractory to standard therapies and a life expectancy of ≥6 months from the time tissue is obtained. A minimum of 6 (≤20) subjects will be enrolled to receive every other week subcutaneous injection of 240 μg AutoSynVax™ vaccine + 50 μg QS-21 Stimulon® adjuvant for up to 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AutoSynVax™ vaccine | AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2018-12-01
- Completion
- 2019-12-01
- First posted
- 2016-12-14
- Last updated
- 2020-06-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02992977. Inclusion in this directory is not an endorsement.